CIK 0001599298 · Large accelerated filer
Summit Therapeutics Inc.
Sign in to watch- Ticker
- SMMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 371979717
- Phone
- 305-203-2034
- Business address
- 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
- Former names
- Summit Therapeutics plc, Summit Corp plc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-02 | Soni Manmeet Singh Chief Operating Officer | Grant or award · Stock Option (right to buy) | +1,100,000 | 1,100,000 | ||
| 2024-04-02 | Anand Bhaskar Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2024-03-27 | Zanganeh Mahkam Chief Executive Officer | Purchase | +26,000 | $3.72 | $97K | 520,814 |
| 2024-03-27 | Zanganeh Mahkam Chief Executive Officer | Purchase | +34,321 | $3.72 | $128K | 24,923,800 |
| 2024-03-27 | Zanganeh Mahkam Chief Executive Officer | Purchase | +20,000 | $3.71 | $74K | 50,000 |
| 2024-03-26 | Zanganeh Mahkam Chief Executive Officer | Purchase | +30,000 | $3.75 | $113K | 30,000 |
| 2024-03-26 | Dhingra Ankur Chief Financial Officer | Purchase | +100,000 | $3.75 | $375K | 354,958 |
| 2024-01-02 | Cesano Alessandra Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2024-01-02 | Cesano Alessandra Director | Grant or award · Stock Option (right to buy) | +21,363 | $1.32 | $28K | 56,363 |
| 2024-01-02 | Booth Robert F. Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2024-01-02 | Booth Robert F. Director | Grant or award · Stock Option (right to buy) | +47,651 | $1.32 | $63K | 82,651 |
| 2024-01-02 | Clark Kenneth A Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2024-01-02 | Clark Kenneth A Director | Grant or award · Stock Option (right to buy) | +70,492 | $1.32 | $93K | 105,492 |
| 2024-01-02 | Mahatme Ujwala Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2024-01-02 | Mahatme Ujwala Director | Grant or award · Stock Option (right to buy) | +52,575 | $1.32 | $69K | 87,575 |
| 2024-01-02 | Xia Yu Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2024-01-02 | Xia Yu Director | Grant or award · Stock Option (right to buy) | +200,000 | 235,000 | ||
| 2024-01-02 | DUGGAN ROBERT W Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +74,545 | $1.32 | $98K | 74,545 |
| 2023-12-13 | Dhingra Ankur Chief Financial Officer | Purchase | +700 | $2.15 | $2K | 235,258 |
| 2023-12-13 | Dhingra Ankur Chief Financial Officer | Purchase | +19,700 | $2.17 | $43K | 254,958 |
Page 5 of 9 · 163 trades